0000000000516193
AUTHOR
Maria Gabriella Cataldo
Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months
Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…
Treatment of patients with duodenal ulcer positive for helicobacter pylori infection: ranitidine or omeprazole associated with colloidal bismuth subcitrate plus amoxicillin
Abstract This study evaluated treatment of patients affected with duodenal ulcer positive for Helicobacter pylori . We compared patients treated with ranitidine plus amoxicillin plus colloidal bismuth subcitrate (n = 20) with patients treated with omeprazole plus amoxicillin plus colloidal bismuth subcitrate (n = 20) with regard to: (1) healing of duodenal ulcer; (2) eradication of H pylori ; and (3) recurrence of ulcer. Baseline and follow-up for 24 months were performed through clinical, laboratory, and endoscopic tests. The ulcer healing rate was 95% in the ranitidine group and 100% in the omeprazole group; the H pylori eradication rate was 90% and 95%, respectively. During follow-up, on…